Future Directions in Treatment of Small Cell Lung Cancer
Panelists conclude their discussion by commenting on areas of unmet need and sharing personal perspectives on factors that may change clinical practice for SCLC in the future.
Emerging Treatments in SCLC: Impact of Targeted Therapy
Key opinion leaders in lung cancer share personal thoughts on the potential for bispecific agents and the overall impact of inhibiting molecular targets.
Emerging Treatments in SCLC: Triplets + Limited-Stage Disease
Anne Chiang, MD, PhD, reviews the study design of 2 clinical trials, adding a third agent to the standard-of-care regimen of chemotherapy plus I/O; Stephen Liu, MD, discusses clinical trials in limited-stage disease.
Emerging Treatments in SCLC: Targeting DNA Damage
Thoracic oncology expert Vivek Subbiah, MD, provides an overview of recent clinical trials studying agents targeting DNA damage for the treatment of small cell lung cancer.
Emerging Treatments in SCLC: Bispecific Antibodies
Expert panelists weigh in on emerging data from recent presentations on small cell lung cancer, including novel immunotherapy approaches such as bispecific antibodies targeting DLL3 or therapies targeting TIGIT.
SCLC: Rechallenging With Chemotherapy + I/O
Anne Chiang, MD, PhD, renowned expert in thoracic oncology, guides a discussion on whether to rechallenge with chemotherapy + I/O after progression of small cell lung cancer.
SCLC: Second-Line Options and Supportive Care
Key opinion leaders in thoracic oncology provide insights into second-line treatment for patients with relapsed/refractory small cell lung cancer and comment on the role of trilaciclib in managing cisplatin-associated neutropenia.
Single Agent I/O Therapy for Relapsed/Refractory
Lung cancer expert Anne Chiang, MD, PhD, considers the recent withdrawal of FDA-accelerated approval for nivolumab and pembrolizumab for patients with relapsed extensive-stage small cell lung cancer.
Treatment After Progression of SCLC: Lurbinectedin
Vivek Subbiah, MD, reviews the safety and efficacy of treatment with lurbinectedin in patients who have platinum-sensitive relapsed small cell lung cancer.
Future Directions in ES SCLC
Panelists reflect on treatment considerations for asymptomatic brain metastases, progress in biomarker research, and frequency of administering checkpoint inhibitors.
Treatment Considerations: Chemotherapy + IO in ES SCLC
Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.
First-Line Therapy in ES SCLS: KEYNOTE-604
Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.
First-Line Therapy in ES SCLC: CASPIAN
Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.
First-Line Therapy in ES SCLC: IMpower133
Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.
WCLC Updates in Small Cell Lung Cancer
Panelists provide first impressions on recent clinical trials in the treatment of small cell lung cancer and comment on the safety and efficacy of study treatments.
WCLC Updates in Locally Advanced NSCLC
Key opinion leaders provide insights on chemotherapy and radiotherapy in patients with unresectable, locally advanced non–small cell lung cancer (NSCLC).
WCLC Updates in Neoadjuvant Therapy for NSCLC
Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).
WCLC Updates in Immunotherapy for NSCLC
Key opinion leaders discuss recent trial data on the clinical efficacy of immunotherapy for the treatment of non–small cell lung cancer (NSCLC).
WCLC Updates on the Emergence of ADCs in NSCLC
Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).
WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).
Multidisciplinary Management of Patients With Stage III NSCLC
Integrating Perioperative Immunotherapy Strategies in NSCLC
Molecular testing in Patients With Metastatic NSCLC
ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC
Varied Timing of IO Therapy in Patients With Stage III NSCLC
Treating for Stage III NSCLC After Progression on Durvalumab
Durvalumab in Stage III NSCLC Based on Performance Status
PACIFIC Trial: Durvalumab Following Chemotherapy for Stage III NSCLC
Mediastinal Staging in Non–Small Cell Lung Cancer
Dr. Liu on the CheckMate-032 Trial in SCLC
Stephen Liu, MD, discusses the CheckMate-032 trial in small cell lung cancer.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
2 Clarke Drive Cranbury, NJ 08512